Important : Never use sterile water (no preservative)
WATCH | WHO recommends GLP-1 therapies for obesity: Health Canada has also listed known risks associated with the use of genuine GLP-1 products, including severe gastrointestinal problems, pancreatitis, worsening kidney injury and low blood sugar, particularly if combined with other medications
doi: 10.1186/s12891-022-05396-5 Summary Keywords type 2 diabetes, osteoporosis, GLP-1 receptor agonists, electronic medical records, cohort study, bone metabolism, fracture risk Citation Chen M, Lyu Y, Zhao J, Han X, Huang T, Yang T and Zhou Y (2025) Use of GLP-1 receptor agonist and risk of osteoporosis among patients with type 2 diabetes: a real-world study
If any powder remains, leave the vial undisturbed and check again after 10-15 minutes before attempting additional swirling
Qi H, Shen D, Jiang C, Wang H, Chang M
A CU Anschutz researcher is overseeing a clinical trial for orforglipron, and a patient shares her experience in the trial